Circulation Research · 1993 · 55 citations · 14 references
MedicineCardiologyPharmacologyIon Channel BiophysicsMolecular PharmacologyPharmacodynamicsAntiarrhythmic TherapyArrhythmia PharmacotherapyCardiac Ion ChannelsCardiac MedicationsIon Channel PharmacologyIon Channel PhysiologyAntiarrhythmic Drug EffectsAntiarrhythmic PharmacologyBinding CapacityDofetilide TherapyDrug Binding To Ion ChannelsLigand BlockadePotassium Channel BlockadePotassium Channel Pharmacology
Class III antiarrhythmic drugs show promise as effective treatments for the suppression of potentially lethal cardiac arrhythmias. Dofetilide (UK-68,798), is a potent class III antiarrhythmic agent that is presently under clinical investigation. The objective of this study was to determine whether [3H]dofetilide could be used as a specific radioligand for the rapidly activating delayed rectifier K+ channel of the heart. We find that [3H]dofetilide binds to high-affinity sites on guinea pig cardiac myocytes. Competition studies using unlabeled dofetilide indicate that binding is characterized by an IC50 of 100 +/- 30 nM (mean +/- SD, n = 13). Scatchard analyses of binding indicate a Kd of 70 +/- 6 nM and a maximal binding capacity of 0.30 +/- 0.02 pmol/mg protein. [3H]Dofetilide is displaced from guinea pig myocytes by dofetilide, clofilium, quinidine, sotalol, and sematilide with a rank order of potency that correlates with functional blockade of the rapidly activating delayed rectifier K+ current (correlation coefficient, 0.951; slope, 0.99 +/- 0.19; p = 0.014). High-affinity [3H]dofetilide binding is not detected in rat myocytes, which are devoid of delayed rectifier K+ current. We conclude that [3H]dofetilide specifically binds to sites associated with the rapidly activating delayed rectifier K+ channel of guinea pig myocardium.
14